Answer
Pazopanib is indicated for adults with selective subtypes of advanced soft-tissue sarcoma who received prior chemotherapy for metastatic disease or progressed within 12 months after (neo)adjuvant therapy, with efficacy and safety established only in certain histological tumour subtypes.
Sources for this answer
- Pazopanib 200 mg film-coated tabletsDr. Reddy's Laboratories (UK) Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 1Document updated
Sources checked